Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Expression of CD8+ and Foxp3+ T Lymphocyte as Predictor for Response to Neoadjuvant Chemotherapy in Stage III Breast Cancer

The Indonesian Biomedical Journal · Vol. 17 No. 3 (2025) · hlm. 287–294

DOI
10.18585/inabj.v17i3.3680
ISSN
2085-3297, 2355-9179
Terbit
2025-06-16
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: Neoadjuvant chemotherapy (NAC) in breast cancer is usually utilized to eradicate micro-metastasis, induce apoptosis in tumor cells, and reduce the primary tumor size, enabling surgical intervention. Recent studies have shown that tumor-infiltrating lymphocytes (TILs), especially cytotoxic CD8+ T cells and immunosuppressive Foxp3+ regulatory T cells, influence tumor response to treatment. However, their role as predictive markers for NAC response remains unclear. Therefore, this study was performed to investigate whether high expression of CD8+ and low expression of Foxp3+ T lymphocytes are associated with better response to NAC in stage III breast cancer patients.METHODS: Total of 60 biopsy samples from stage III breast cancer patients were included, comprising 30 subjects in the response group (+) and 30 subjects in the non-response group (−). The expression levels of CD8+ and Foxp3+ T lymphocytes in tumor tissue were assessed semi-quantitatively by immunohistochemistry (IHC), using a scoring system based on the proportion and intensity of positively stained cells (Black’s grading criteria).RESULTS: Stage III breast cancer with high expression of CD8+ T lymphocytes was significantly associated with a better response to NAC (p=0.004; OR=6.882). Meanwhile, low expression of Foxp3+ T lymphocytes was not significantly associated with chemotherapy response (p=0.067; OR=3.250). A higher tumor grade was also associated with an improved response to treatment. The probability of achieving a positive response to NAC in subjects presenting with high CD8+ expression, low Foxp3+ expression, and high tumor grade was estimated at 96.98%.CONCLUSION: The combination of high expression of CD8+ T lymphocyte, low expression of Foxp3+ T lymphocyte and high tumor grade might be useful to predict good response to NAC in stage III breast cancer.KEYWORDS: CD8+ T lymphocyte, Foxp3+ T lymphocyte, neoadjuvant chemotherapy, breast cancer

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 161 tautan kepenulisan bersama · 48 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Udayana University
  • Universitas Dhyana Pura
  • Rumah Sakit Umum Pusat Sanglah Denpasar
  • Universitas Gadjah Mada
  • Myitkyina University
  • STIKES Bina Usada Bali
  • Universitas Airlangga
  • Organisasi lain
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Nyoman GoldenUdayana University4
Ni Nyoman Ayu DewiUdayana University3
I Gede WidhiantaraUniversitas Dhyana Pura2
Putu Angga WiradanaUniversitas Dhyana Pura2
Nico Odolf YordaniusUdayana University2
I Ketut WiargithaUdayana University2
I Wayan PeriadijayaUdayana University2
Bismantara Aditya PutraUdayana University2
Kadek Budi SantosaUdayana University2
Gede Wirya Kusuma DuarsaUdayana University2
Hamsu KadriyanUniversity of Mataram2
I Wayan Gede Artawan Eka PutraUdayana University2
Achmad Chusnu RomdhoniUniversitas Airlangga2
I Gusti Kamasan Nyoman ArijanaUdayana University2
Ni Ketut SusilawatiAfiliasi tidak diketahui2
Wayan SuardanaRumah Sakit Umum Pusat Sanglah Denpasar2
Sri MaliawanRumah Sakit Umum Pusat Sanglah Denpasar2
SutirtaYasa, I W. PAfiliasi tidak diketahui1
Anak Agung Bawa PutraUdayana University1
Ida Bagus Putra ManuabaUdayana University1
I Made SiakaUdayana University1
I Made BaktaUdayana University1
Karna WijayaUniversitas Gadjah Mada1
Parwata Oka Adi ParwataUdayana University1
I Made SukadanaUdayana University1
I Wayan Putu Sutirta YasaUdayana University1
Anak Agung Ngurah SubawaUdayana University1
Sin War NawMyitkyina University1
I Wayan RosianaUniversitas Dhyana Pura1
Anak Agung Ayu Putri PermatasariUniversitas Dhyana Pura1
Luh Putu WidiastiniSTIKES Bina Usada Bali1
Anom SuardikaUdayana University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Expression of CD8+ and Foxp3+ T Lymphocyte as Predictor for Response to Neoadjuvant Chemotherapy in Stage III Breast Cancer</dc:title><dc:creator>I Nyoman Wawan Tirtha Yasa</dc:creator><dc:creator>I Wayan Sudarsa</dc:creator><dc:creator>I Wayan Niryana</dc:creator><dc:creator>Ni Putu Sriwidyani</dc:creator><dc:creator>I Made Jawi</dc:creator><dc:creator>I Wayan Putu Sutirta Yasa</dc:creator><dc:creator>Ida Bagus Tjakra Wibawa Manuaba</dc:creator><dc:creator>Ida Bagus Made Suryawisesa</dc:creator><dc:subject>CD8+ T cells</dc:subject><dc:subject>Foxp3+ regulatory T cells</dc:subject><dc:subject>neoadjuvant chemotherapy response</dc:subject><dc:subject>stage III breast cancer</dc:subject><dc:subject>tumor-infiltrating lymphocytes</dc:subject><dc:subject>predictive biomarkers</dc:subject><dc:subject>tumor grade</dc:subject><dc:description xml:lang="en">BACKGROUND: Neoadjuvant chemotherapy (NAC) in breast cancer is usually utilized to eradicate micro-metastasis, induce apoptosis in tumor cells, and reduce the primary tumor size, enabling surgical intervention. Recent studies have shown that tumor-infiltrating lymphocytes (TILs), especially cytotoxic CD8+ T cells and immunosuppressive Foxp3+ regulatory T cells, influence tumor response to treatment. However, their role as predictive markers for NAC response remains unclear. Therefore, this study was performed to investigate whether high expression of CD8+ and low expression of Foxp3+ T lymphocytes are associated with better response to NAC in stage III breast cancer patients.METHODS: Total of 60 biopsy samples from stage III breast cancer patients were included, comprising 30 subjects in the response group (+) and 30 subjects in the non-response group (−). The expression levels of CD8+ and Foxp3+ T lymphocytes in tumor tissue were assessed semi-quantitatively by immunohistochemistry (IHC), using a scoring system based on the proportion and intensity of positively stained cells (Black’s grading criteria).RESULTS: Stage III breast cancer with high expression of CD8+ T lymphocytes was significantly associated with a better response to NAC (p=0.004; OR=6.882). Meanwhile, low expression of Foxp3+ T lymphocytes was not significantly associated with chemotherapy response (p=0.067; OR=3.250). A higher tumor grade was also associated with an improved response to treatment. The probability of achieving a positive response to NAC in subjects presenting with high CD8+ expression, low Foxp3+ expression, and high tumor grade was estimated at 96.98%.CONCLUSION: The combination of high expression of CD8+ T lymphocyte, low expression of Foxp3+ T lymphocyte and high tumor grade might be useful to predict good response to NAC in stage III breast cancer.KEYWORDS: CD8+ T lymphocyte, Foxp3+ T lymphocyte, neoadjuvant chemotherapy, breast cancer</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2025-06-16</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.18585/inabj.v17i3.3680</dc:identifier><dc:identifier>10.18585/inabj.v17i3.3680</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 17 No 3 (2025); 287-294</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/3680/780</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>